Clinical Trials Logo

Communicable Diseases clinical trials

View clinical trials related to Communicable Diseases.

Filter by:

NCT ID: NCT06425250 Recruiting - Clinical trials for Campylobacter Infections

Campylobacter Spp. Bone and Joint Infection: a Retrospective Cohort Study

Campylo-BJI
Start date: January 1, 2024
Phase:
Study type: Observational

Campylobacter bacteria, a Gram-negative bacillus commensal in the digestive tract of many animals and mainly responsible for human infections with digestive origins, has been little studied in the field of osteoarticular infections (OAI). Campylobacter spp. are, however, well described, mainly for C. fetus, and pose a dual therapeutic problem: i) a capacity for persistence due to the capacity of most strains to form biofilm; and ii) potential resistance to many antibiotics. The management of IOA caused by Campylobacter spp. is not codified, and is based on small series of cases reported in the literature.

NCT ID: NCT06425081 Recruiting - Clinical trials for Microbial Colonization

Investigating the Impact of Humiome B2 (Colon Delivered Riboflavin) and Riboflavin-overproducer Probiotic Strain Limosilactobacillus Reuteri AMBV339 on Intestinal and Vaginal Microbiome and Health of Healthy Adult Women (The VIAB2L Project)

VIAB2L
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn if the probiotic strain Limosilactobacillus reuteri AMBV339 or colon-delivered riboflavin or their combination can change the gut and vaginal microbiome and metabolomics. It will also learn about the safety of the investigational product. The main questions it aims to answer are: Do the probiotic strain Limosilactobacillus reuteri AMBV339 or colon-delivered riboflavin or their combination modify gut microbiome? Do the probiotic strain Limosilactobacillus reuteri AMBV339 or colon-delivered riboflavin or their combination modify gut microbiome? Researchers will compare the probiotic strain Limosilactobacillus reuteri AMBV339 or colon-delivered riboflavin or their combination to a placebo (a look-alike substance that contains no drug) to see if they can change gut and vaginal microbiome. Intervention period is 28 days.

NCT ID: NCT06420934 Recruiting - Clinical trials for Surgical Wound Infection

Surgical Handwashing: Drying With One or Two Surgical Towels

Start date: April 26, 2024
Phase: N/A
Study type: Interventional

This study aims to determine whether the use of two sterile towels for drying after surgical handwashing results in fewer contamination events compared to the use of only one towel among healthcare personnel. This randomized, multicenter, superiority-controlled trial will enroll up to 72 healthcare workers and surgical residents from three hospitals in Bogotá, Colombia. A fluorescent product will simulate bacteria, and contamination will be assessed by evaluating the presence of fluorescent cream after hand drying technique with either two or one surgical sterile towel. Data will be collected through REDCap and deidentified. Differences in the proportion of contamination between the two groups will be assessed using an exact Fischer test, and confounding variables will be included in the analysis through logistic multivariate regression, with a significance level set a priori at 0.05. Results will be submitted for publication in a peer-reviewed journal.

NCT ID: NCT06418048 Recruiting - Clinical trials for Infective Endocarditis

INfectious DIsease REgistry BIObank

INDI-REBIO
Start date: February 1, 2024
Phase:
Study type: Observational [Patient Registry]

Prospective observational study designed to describe the clinical, laboratory, imaging, microbiological characteristics and treatment of specific infectious diseases, with the addition of a dedicated biobank.

NCT ID: NCT06416709 Recruiting - Lung Injury Clinical Trials

Stem Cell Treatment for Lung Injury Caused by Major Infectious Diseases

Start date: May 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for Lung injury caused by major infectious diseases.

NCT ID: NCT06410053 Recruiting - Infectious Disease Clinical Trials

The All Ireland Infectious Diseases Cohort Project

AIID
Start date: March 2011
Phase:
Study type: Observational

The All-Ireland Infectious Diseases (AIID) Cohort is a multicentre, prospective, longitudinal observational cohort that enrols consecutive adult subjects attending participating institutions for infectious disease services. This is an ongoing prospective observational cohort of unlimited duration.

NCT ID: NCT06397066 Recruiting - Clinical trials for Helicobacter Pylori Infection

White Light Endoscopy and Magnifying Endoscopy in Assessing the Status of Hp Infection

Start date: May 1, 2024
Phase:
Study type: Observational

By comparing the characteristics of Helicobacter pylori (Hp) infection under magnifying endoscopy and white light endoscopy, and making judgments of Hp infection status, the advantages and disadvantages of the two endoscopic examination methods are summarized to improve the accuracy of subsequent endoscopic Hp infection status judgments.

NCT ID: NCT06392568 Recruiting - Critical Illness Clinical Trials

Epidemiological Features of Emergent Highly Resistant Bacteria in Tunisian Intensive Care Units

NOSOREA3
Start date: April 1, 2024
Phase:
Study type: Observational

Investigate the epidemiology, risk factors and impact on clinical practice of healthcare-associated infections with emergent highly drug-resistant (eHDR) pathogens, particularly carbapenem resistant enterobacteriaceae and glycopeptides-resistant enterococcus.

NCT ID: NCT06390878 Recruiting - Atopic Dermatitis Clinical Trials

Nationwide Research on the Rewilding of Kindergarten Yards

Vahvistu
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

Biodiversity is essential for nature and human well-being. Land use has reduced biodiversity in cities that is associated with altered commensal microbiota and a rising burden of immunological disorders among urban children. The investigators will estimate how rewilding of kindergarten yards affects commensal microbiome, prevalence of allergies, asthma, atopic dermatitis and infections, cortisol levels, cognitive skills and plasma cytokine levels of children. Our specific aims are: To assess if rewilding diversifies health-associated skin, saliva and gut microbiota and reduces infectious diseases and atopic or allergic symptoms. Assess whether the rewilding has positive effects on cognitive skills. Assess whether the rewilding changes cortisol and plasma cytokine levels. The investigators will recruit altogether 320 (160 per treatment) study subjects aged between 1-5 to questionnaire study (Task 2), from which 120 study subjects will be analyzed more detailed using microbiological and blood samples (Task 1).

NCT ID: NCT06390696 Recruiting - Atopic Dermatitis Clinical Trials

Sand Play - the Effect of Biodiversity Exposure on Atopic Dermatitis

BIWE
Start date: May 26, 2023
Phase: N/A
Study type: Interventional

The prevalence of atopic dermatitis has increased along with urbanization and biodiversity loss. According to biodiversity hypothesis, the main reason is urban lifestyle and reduced contact to microbial diversity. Previous studies indicate association between atopic dermatitis and exposure to natural microbes in childhood. Sand Play - the Effect of Biodiversity Exposure on Atopic Dermatitis will investigate whether the exposure to microbial diversity in sandbox reduces the symptoms of atopic dermatitis, alters commensal microbiota and modifies immune regulation in children.